Polymorphic ventricular tachycardia with mutation in KCNJ2: case report
By
Cuizhen Zhou
Juan Chen
Cuilan Hou
Tingting Xiao
Li Zhang
June 16, 2026
Clinical Scorecard: Case Study of Polymorphic Ventricular Tachycardia Linked to KCNJ2 Gene Mutation
At a Glance
Category Detail
Condition Key Mechanisms Target Population Care Setting Cardiology clinics and hospitals specializing in genetic arrhythmias.
Key Highlights
First patient: 13-year-old girl with periodic paralysis and prolonged QT interval; treatment outcomes need clarification. Second patient: 5-year-old boy with thumb adduction and significant PVC burden; specify flecainide's effectiveness. Guideline-Based Recommendations
Diagnosis
Management
Sequential treatment with antiarrhythmic drugs such as metoprolol and flecainide, with rationale for each choice. Monitoring & Follow-up
Risks
Patient & Prescribing Data
Flecainide may be a promising therapeutic option despite poor response to other antiarrhythmics; detail variability in treatment response.
Clinical Best Practices
Utilize in silico tools for evaluating the pathogenicity of KCNJ2 mutations; provide supporting evidence. Consider radiofrequency catheter ablation in cases with persistent arrhythmias; include references. Related Resources & Content
